Gastric cancer is a highly heterogeneous disease, displaying a complex genomic landscape and an unfavorable outcome with standard therapies. Based on distinctive genomic alterations, novel targeted agents have been developed with the aim of personalizing treatments and improving patient outcome. However, a subgroup of patients is primarily treatment-resistant, and even in the initially sensitive population, secondary resistance emerges, thus limiting therapeutic benefit. In this review, we summarize the clinical data about standard targeted agents in gastric cancer, specifically anti-HER2 treatments and antivascular therapies. We also illustrate the available evidence regarding molecular mechanisms of resistance to these agents and we discuss potential strategies for new targeted treatments that could overcome such resistance.

Genomic markers of resistance to targeted treatments in gastric cancer : potential new treatment strategies / A. Raimondi, F. Nichetti, G. Peverelli, M. Di Bartolomeo, F. De Braud, F. Pietrantonio. - In: PHARMACOGENOMICS. - ISSN 1462-2416. - 19:13(2018 Aug), pp. 1047-1068.

Genomic markers of resistance to targeted treatments in gastric cancer : potential new treatment strategies

F. Nichetti;G. Peverelli;F. De Braud;F. Pietrantonio
2018-08

Abstract

Gastric cancer is a highly heterogeneous disease, displaying a complex genomic landscape and an unfavorable outcome with standard therapies. Based on distinctive genomic alterations, novel targeted agents have been developed with the aim of personalizing treatments and improving patient outcome. However, a subgroup of patients is primarily treatment-resistant, and even in the initially sensitive population, secondary resistance emerges, thus limiting therapeutic benefit. In this review, we summarize the clinical data about standard targeted agents in gastric cancer, specifically anti-HER2 treatments and antivascular therapies. We also illustrate the available evidence regarding molecular mechanisms of resistance to these agents and we discuss potential strategies for new targeted treatments that could overcome such resistance.
gastric cancer; resistance; targeted therapy
Settore MED/06 - Oncologia Medica
PHARMACOGENOMICS
Article (author)
File in questo prodotto:
File Dimensione Formato  
2018 pharmacogenomics.pdf

non disponibili

717.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
pgs-2018-0077.pdf

non disponibili

735.74 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/597228
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 11
social impact